CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Purple Biotech Ltd   (PPBT)
Other Ticker:  
 

Purple Biotech Ltd 's Tangible Leverage Ratio

PPBT's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth




PPBT Tangible Leverage Ratio (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Tangible Equity Change -27.66 % -27.66 % -27.66 % -27.66 % -18.36 %
Y / Y Total Liabilities Change 38.61 % 38.61 % 38.61 % 38.61 % 25.7 %
Tangible Leverage Ratio MRQ 0.15 0.15 0.15 0.15 0.08
Overall Ranking # 151 # 439 # 444 # 446 # 293
Seq. Tangible Equity Change 0 % 0 % 0 % -27.66 % 0 %
Seq. Total Liabilities Change 0 % 0 % 0 % 38.61 % 0 %

New: More PPBT's historic Tangible Leverage Ratio results >>


Comment on PPBT Tangible Leverage Ratio in the forth quarter 2022
Due to repayements of liabilities of 0% Purple Biotech Ltd improved Tangible Leverage Ratio in forth quarter 2022 to 0.15, above the Purple Biotech Ltd 's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 42 other companies have achieved lower Tangible Leverage Ratio than Purple Biotech Ltd in the IV Quarter 2022. While Tangible Leverage Ratio total ranking has improved so far in the forth quarter 2022 to 151, from total ranking in the third quarter 2022 at 439.

Explain Tangible Leverage Ratio?
What is PPBT Market Share?
What are PPBT´s Total Liabilities?
Tangible Leverage Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 71
Overall Market # 151


Tangible Leverage Ratio Statistics
High Average Low
0.36 0.13 0.04
(Dec 31 2019)   (Dec 31 2018)




Financial Statements
Purple Biotech Ltd 's Tangible Equity $ 47 Millions Visit PPBT's Balance sheet
Purple Biotech Ltd 's Total Liabilities $ 7 Millions Visit PPBT's Balance sheet
Source of PPBT's Sales Visit PPBT's Sales by Geography


Cumulative Purple Biotech Ltd 's Tangible Leverage Ratio

PPBT's Tangible Leverage Ratio for the trailling 12 Months

PPBT Tangible Leverage Ratio

 (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Tangible Equity TTM Growth -27.66 % -27.66 % -27.66 % -27.66 % -18.36 %
Y / Y Total Liabilities TTM Growth 38.61 % 38.61 % 38.61 % 38.61 % 25.7 %
Tangible Leverage Ratio TTM 0.15 0.13 0.11 0.09 0.08
Total Ranking TTM # 3 # 3 # 3 # 4 # 218
Seq. Tangible Equity TTM Growth 0 % 0 % 0 % -27.66 % 0 %
Seq. Total Liabilities TTM Growth 0 % 0 % 0 % 38.61 % 0 %

PPBT Company Profile >> Back to PPBT Financial Strength Comparisons >> See PPBT Balance Sheets

TTM Tangible Leverage Ratio Comment
On the trailing twelve months basis Despite of the repayements of liabilities of 0% in the trailling twelve months ending in IV Quarter 2022, Tangible Leverage Ratio improved to 0.15, above Purple Biotech Ltd 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 42, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Purple Biotech Ltd . While total ranking remained unchanged compared to previous 12 month period at no. 3.

Explain Tangible Leverage Ratio?
What is PPBT Market Share?
What are PPBT´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 71
Within the Market # 151


TTM Tangible Leverage Ratio Statistics
High Average Low
0.36 0.13 0.04
(Dec 31 2019)   (Dec 31 2018)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioDec 31 2022 MRQ Total LiabilitiesDec 31 2022 MRQ Tangible Equity
Sinovac Biotech Ltd  0.41 $ 5,193.147  Millions$ 12,702.962  Millions
Oncolytics Biotech Inc   0.41 $ 8.297  Millions$ 20.301  Millions
Calithera Biosciences Inc   0.41 $ 8.284  Millions$ 20.392  Millions
Moonlake Immunotherapeutics  0.40 $ 27.816  Millions$ 68.767  Millions
Regulus Therapeutics Inc   0.40 $ 13.425  Millions$ 33.229  Millions
Neubase Therapeutics inc   0.40 $ 7.359  Millions$ 18.224  Millions
Onconova Therapeutics inc   0.40 $ 11.289  Millions$ 28.309  Millions
Integrated Biopharma Inc  0.40 $ 7.400  Millions$ 18.652  Millions
Liminal Biosciences Inc   0.39 $ 10.916  Millions$ 27.735  Millions
Hookipa Pharma inc   0.39 $ 39.963  Millions$ 102.517  Millions
Cue Biopharma Inc   0.39 $ 25.601  Millions$ 65.683  Millions
Enveric Biosciences Inc   0.39 $ 5.517  Millions$ 14.292  Millions
Magenta Therapeutics Inc   0.38 $ 40.687  Millions$ 105.958  Millions
Longeveron Inc   0.38 $ 6.910  Millions$ 18.094  Millions
Nurix Therapeutics Inc   0.37 $ 113.063  Millions$ 303.696  Millions
Thorne Healthtech Inc   0.37 $ 42.282  Millions$ 114.781  Millions
Marker Therapeutics inc   0.37 $ 7.205  Millions$ 19.601  Millions
Arrowhead Pharmaceuticals Inc   0.37 $ 141.342  Millions$ 384.835  Millions
Sunshine Biopharma Inc   0.37 $ 7.616  Millions$ 20.851  Millions
Renovorx Inc   0.36 $ 2.204  Millions$ 6.163  Millions
Cellectar Biosciences Inc   0.35 $ 5.478  Millions$ 15.508  Millions
Tiziana Life Sciences Ltd  0.35 $ 6.906  Millions$ 19.571  Millions
Vertex Pharmaceuticals Inc  0.35 $ 4,238.200  Millions$ 12,221.100  Millions
Zevra Therapeutics Inc   0.35 $ 29.722  Millions$ 85.807  Millions
Zymeworks Inc   0.34 $ 155.769  Millions$ 454.557  Millions
Neximmune Inc   0.33 $ 10.759  Millions$ 32.300  Millions
Generation Bio Co   0.33 $ 93.771  Millions$ 282.493  Millions
Reviva Pharmaceuticals Holdings Inc   0.33 $ 4.088  Millions$ 12.316  Millions
Histogen Inc   0.33 $ 4.430  Millions$ 13.376  Millions
Bolt Biotherapeutics Inc   0.33 $ 56.301  Millions$ 171.506  Millions

Date modified: 2023-03-23T13:12:32+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com